Athira Pharma (NASDAQ:ATHA) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Athira Pharma (NASDAQ:ATHAGet Rating) released its quarterly earnings data on Thursday. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.01), MarketWatch Earnings reports.

Shares of ATHA traded up $0.32 during mid-day trading on Friday, reaching $8.28. 241,700 shares of the company were exchanged, compared to its average volume of 274,963. Athira Pharma has a 52 week low of $7.56 and a 52 week high of $23.64. The stock has a market capitalization of $311.49 million, a PE ratio of -4.79 and a beta of 3.25. The business has a 50 day simple moving average of $11.01 and a two-hundred day simple moving average of $11.72.

In related news, Director Kelly A. Romano acquired 8,000 shares of the stock in a transaction dated Thursday, March 31st. The stock was bought at an average cost of $13.11 per share, for a total transaction of $104,880.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 14.90% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. bought a new position in shares of Athira Pharma during the third quarter worth about $112,000. Metropolitan Life Insurance Co NY increased its holdings in Athira Pharma by 42.9% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 10,300 shares of the company’s stock worth $134,000 after purchasing an additional 3,091 shares in the last quarter. Bank of America Corp DE increased its holdings in Athira Pharma by 56.3% in the second quarter. Bank of America Corp DE now owns 16,749 shares of the company’s stock worth $172,000 after purchasing an additional 6,036 shares in the last quarter. MetLife Investment Management LLC increased its holdings in Athira Pharma by 85.7% in the fourth quarter. MetLife Investment Management LLC now owns 13,703 shares of the company’s stock worth $179,000 after purchasing an additional 6,323 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in Athira Pharma by 55.0% in the fourth quarter. Parametric Portfolio Associates LLC now owns 23,882 shares of the company’s stock worth $311,000 after purchasing an additional 8,477 shares in the last quarter. Institutional investors own 69.76% of the company’s stock.

Several analysts recently weighed in on the company. JMP Securities reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Athira Pharma in a research note on Friday, March 25th. Zacks Investment Research lowered Athira Pharma from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. BTIG Research started coverage on Athira Pharma in a research report on Tuesday. They issued a “buy” rating and a $33.00 target price for the company. Finally, Berenberg Bank started coverage on Athira Pharma in a research report on Thursday, April 21st. They issued a “buy” rating and a $33.00 target price for the company. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $29.40.

About Athira Pharma (Get Rating)

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease.

Featured Articles

Earnings History for Athira Pharma (NASDAQ:ATHA)

Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.